63
Participants
Start Date
November 29, 2023
Primary Completion Date
July 2, 2025
Study Completion Date
July 2, 2025
Tumor lysate, particle only (TLPO) vaccine
A novel technology in which a patient's tumor lysate (TL) is loaded into microparticles for DC phagocytosis and antigen processing allows for vaccine efficacy, while minimizing tissue demands by only requiring approximately 250-500ug of tumor. Immature DCs avidly phagocytose small particles in the range of 1-5 microns. Tumor tissue collected from the patient undergoes a process of freeze-thaw cycling to create a TL suspension. The microparticles, yeast-cell wall particles (YCWP), are created from Saccharomyces cerevisiae by NaOH/HCl digestion of all non-cell wall components and washed, producing β-glycan shells. The TL is then loaded into these YCWP.
Southside Medical Center, Greenville
Lead Sponsor
Collaborators (1)
LumaBridge
INDUSTRY
Elios Therapeutics, LLC
INDUSTRY